TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25939332

Group type: EXPERIMENTAL
Intervention: Test formulation of pregabalin 300 mg hard capsules
Number of subjects: 40

Group type: COMPARATOR
Intervention: Reference formulation of pregabalin 300 mg hard capsules
Number of subjects: 40
Study: 23945406

Group type: EXPERIMENTAL
Intervention: Korean red ginseng (6 g daily for 12 weeks)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 68
Study: 22048221

Group type: EXPERIMENTAL
Intervention: 300 mg clopidogrel + PA32540 followed by 75 mg clopidogrel + PA32540 on days 2-7
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PA32540 in the morning + 300 mg clopidogrel 10 h later on day 1 and PA32540 in the morning + 75 mg clopidogrel 10 h later on days 2-7
Number of subjects: 30

Group type: COMPARATOR
Intervention: 300 mg clopidogrel + 325 mg ECASA followed by 75 mg clopidogrel + 325 mg ECASA on days 2-7
Number of subjects: 30
Study: 19218294

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (50 mg/day)
Number of subjects: 29133
Study: 16113579

Group type: EXPERIMENTAL
Intervention: Oronasopharyngeal suction (ONPS)
Number of subjects: 140

Group type: COMPARATOR
Intervention: No suction
Number of subjects: 140
Study: 12850527

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 0
Study: 10815450

Group type: EXPERIMENTAL
Intervention: Nutritional education program for children
Number of subjects: 0
Study: 8771623

Group type: EXPERIMENTAL
Intervention: Testosterone substitution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amenorrheic women
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normally menstruating women
Number of subjects: 0
Study: 1462974

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 2982387

Group type: EXPERIMENTAL
Intervention: etomidate 0.3 mg kg‐1
Number of subjects: 12

Group type: COMPARATOR
Intervention: thiopentone 5 mg kg‐1
Number of subjects: 12
Study: 31033527

Group type: EXPERIMENTAL
Intervention: Phenazopyridine 200 mg on postoperative day 1
Number of subjects: 152

Group type: COMPARATOR
Intervention: No additional phenazopyridine
Number of subjects: 152
Study: 31829274

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.4 μg/kg/h, increased by 0.2 μg/kg/h per hour up to 0.8 μg/kg/h; neonates: 0.2 μg/kg/h, increased by 0.1 μg/kg/h per hour up to 0.4 μg/kg/h)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 29994994

Group type: EXPERIMENTAL
Intervention: Aδ fiber activation through CO2 laser delivered ultrafast short constant-temperature heat pulses
Number of subjects: 0

Group type: COMPARATOR
Intervention: C fiber activation through CO2 laser delivered ultrafast short constant-temperature heat pulses
Number of subjects: 0
Study: 27373542

Group type: EXPERIMENTAL
Intervention: Home insertion of etonogestrel implant
Number of subjects: 37

Group type: COMPARATOR
Intervention: Office insertion of etonogestrel implant
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Home visits
Number of subjects: 37

Group type: COMPARATOR
Intervention: Office visits
Number of subjects: 37
Study: 24642719

Group type: EXPERIMENTAL
Intervention: Low glycemic index (GI) diet advice
Number of subjects: 621

Group type: COMPARATOR
Intervention: Control group (no low GI advice)
Number of subjects: 621
Study: 22614150

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) supplementation (1 g/kg loading dose and 0.17 g/kg every 6 minutes)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (PL) supplementation (equal volume of saccharin and aspartame solution)
Number of subjects: 6
Study: 20456697

Group type: EXPERIMENTAL
Intervention: Liberal strategy with RBC storage time > 14 days
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Restrictive strategy with RBC storage time > 21 days
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Combined groups with RBC storage time > 14 days
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Combined groups with RBC storage time > 21 days
Number of subjects: 455
Study: 18729687

Group type: EXPERIMENTAL
Intervention: Single context extinction (extinction to alcohol cues in the same context for 3 sessions followed by a context shift at the fourth session)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Multiple context extinction (extinction to alcohol cues in different contexts each day for all 4 sessions)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Pseudoextinction control condition (exposure to neutral cues in the same context for 3 sessions followed by exposure to alcohol cues at the fourth session)
Number of subjects: 73
Study: 12775025

Group type: EXPERIMENTAL
Intervention: Personalized chemotherapy based on gene expression profiles
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (standard treatment without gene expression profiles)
Number of subjects: 30
Study: 11778496

Group type: EXPERIMENTAL
Intervention: M. vaccae + chemotherapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Chemotherapy only (Control)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by M. vaccae (Self control)
Number of subjects: 90
Study: 9316525

Group type: EXPERIMENTAL
Intervention: Dalteparin (150 IU/kg body weight every 12 h during the hospital period)
Number of subjects: 776

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 776
Study: 8165385

Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa (25/100 mg and 50/200 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Propoxyphene (100 mg and 200 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2427838

Group type: EXPERIMENTAL
Intervention: Celiprolol 200 mg once daily for one week, followed by 400 mg once daily for the third week
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Celiprolol (exact dosage not specified during crossover phase)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 29520465

Group type: EXPERIMENTAL
Intervention: Ventricular dysfunction (RV ejection fraction < 44% or RV fractional area of change < 35%)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Presence of Blalock-Taussig (BT) shunt, large RV, post-Norwood infectious complication, and surgeon performing five or less Norwood procedures per year
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Patients with all four identified risk factors
Number of subjects: 365
Study: 27977774

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study: 24788217

Group type: EXPERIMENTAL
Intervention: Automated data analysis with individualized written advice on appropriate health services (Intervention Group)
Number of subjects: 514

Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 514
Study: 22726105

Group type: EXPERIMENTAL
Intervention: Thymosin α-1 plus peginterferon α-2a (180 μg weekly for 48 weeks and 1.6 mg twice a week for the first 12 weeks)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Peginterferon α-2a monotherapy (180 μg weekly for 48 weeks)
Number of subjects: 51
Study: 19747581

Group type: EXPERIMENTAL
Intervention: 0.6 mg oSCT
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 0.8 mg oSCT
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 18165796

Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 16129366

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy followed by surgery (80 mg/m² cisplatin on day 1, 800 mg/m² fluorouracil on days 1-4, with concurrent radiotherapy of 35 Gy in 15 fractions)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy followed by surgery
Number of subjects: 256

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 256
Study: 12538460

Group type: EXPERIMENTAL
Intervention: Doxorubicin 90 mg/m(2) followed by paclitaxel 250 mg/m(2) (or reverse)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Doxorubicin 60 mg/m(2) and paclitaxel 175 mg/m(2)
Number of subjects: 29
Study: 10024611

Group type: EXPERIMENTAL
Intervention: Prior protein intake of 0.8 g protein. kg‐1. d‐1
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Prior protein intake of 1.4 g protein. kg‐1. d‐1
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Prior protein intake of 2.0 g protein. kg‐1. d‐1
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Amino acid‐based formula diet containing 1 g protein. kg‐1. d‐1
Number of subjects: 3
Study: 8711700

Group type: EXPERIMENTAL
Intervention: Open acromioplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Closed percutaneous acromioplasty
Number of subjects: 0
Study: 1844994

Group type: EXPERIMENTAL
Intervention: 7% glucose polymer beverage containing electrolytes (GP)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Nonnutrient, nonelectrolyte placebo (P)
Number of subjects: 44
Study: 6417996

Group type: EXPERIMENTAL
Intervention: Intermittent nasogastric feeding (2-h bolus administration)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Continuous nasogastric feeding (24 h/day)
Number of subjects: 10
Study: 31005176

Group type: EXPERIMENTAL
Intervention: 3T MRI
Number of subjects: 982

Group type: COMPARATOR
Intervention: 1.5T MRI
Number of subjects: 982
Study: 28939746

Group type: EXPERIMENTAL
Intervention: Radotinib 300 mg
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Radotinib 400 mg
Number of subjects: 241

Group type: COMPARATOR
Intervention: Imatinib 400 mg
Number of subjects: 241
Study: 26511965

Group type: EXPERIMENTAL
Intervention: Waves aquatic exercise classes (n = 67)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (n = 42)
Number of subjects: 109
Study: 25081721

Group type: EXPERIMENTAL
Intervention: Autologous tumor lysate primed mature DC (arm III)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Unprimed mature DC (arm II)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline control (arm I)
Number of subjects: 14
Study: 21523892

Group type: EXPERIMENTAL
Intervention: Intracoronary bolus-only tirofiban (n = 25)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Intravenous bolus plus infusion of tirofiban (n = 24)
Number of subjects: 49
Study: 18975259

Group type: EXPERIMENTAL
Intervention: Heavy weight strength training (HWT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Explosive strength training (EST)
Number of subjects: 16
Study: 17341128

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR), 25% caloric restriction
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Caloric restriction with exercise (CREX), 12.5% caloric restriction + 12.5% increased energy expenditure
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control, 100% of energy requirements
Number of subjects: 36
Study: 15285862

Group type: EXPERIMENTAL
Intervention: Single high dose steroid treatment in addition to intravenous antibiotic therapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Intravenous antibiotic therapy with a single dose placebo
Number of subjects: 62
Study: 11352443

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Moxifloxacin 400mg with ferrous sulfate (Eryfer 100 equivalent to 100mg of Fe2+)
Number of subjects: 12
Study: 9207997

Group type: EXPERIMENTAL
Intervention: Lactobacillus johnsonii La1
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (fermented milk without La1)
Number of subjects: 12
Study: 8355154

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 0.03%
Number of subjects: 233

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 233
Study: 3316309

Group type: EXPERIMENTAL
Intervention: Bendrofluazide 5 mg
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Bendrofluazide 10 mg
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Potassium supplementation (16.8 or 33.6 mmol potassium chloride)
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg + Amiloride 2.5 mg
Number of subjects: 1185

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 50 mg + Amiloride 5 mg
Number of subjects: 1185
Study: 29175360

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 300

Group type: COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Auricular point pressing
Number of subjects: 300
Study: 27692704

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 31

Group type: COMPARATOR
Intervention: Both anesthetics
Number of subjects: 31
Study: 25164306

Group type: EXPERIMENTAL
Intervention: 10-degree laterally wedged insole
Number of subjects: 12

Group type: COMPARATOR
Intervention: Neutral insole
Number of subjects: 12
Study: 22387529

Group type: EXPERIMENTAL
Intervention: telaprevir plus peginterferon/ribavirin
Number of subjects: 161
Study: 21055212

Group type: EXPERIMENTAL
Intervention: Cervical expansive open door laminoplasty (EOLP) with hinge at the inner margin of the lateral mass (wide-open group)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Cervical expansive open door laminoplasty (EOLP) with hinge at the lamina margin (narrow-open group)
Number of subjects: 102
Study: 18407793

Group type: EXPERIMENTAL
Intervention: CoQ(10) 100 mg, riboflavin 10 mg and niacin 50 mg (CoRN) along with tamoxifen (TAM) 10 mg twice a day for 45 days (Group IV)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: CoQ(10) 100 mg, riboflavin 10 mg and niacin 50 mg (CoRN) along with tamoxifen (TAM) 10 mg twice a day for 90 days (Group V)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 10 mg twice a day
Number of subjects: 84
Study: 16422829

Group type: EXPERIMENTAL
Intervention: Intralesional interferon alpha-2b (5 x 10(6) units)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (10 mL saline)
Number of subjects: 39
Study: 12760524

Group type: EXPERIMENTAL
Intervention: Familiar occupations rated by children
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Novel occupations depicted with African Americans
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Children's age and socioeconomic background
Number of subjects: 92
Study: 12950423

Group type: EXPERIMENTAL
Intervention: Asimadoline 0.5 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Asimadoline 1.5 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Asimadoline
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 9877445

Group type: EXPERIMENTAL
Intervention: Betaseron (interferon-beta1b)
Number of subjects: 0
Study: 8556078

Group type: EXPERIMENTAL
Intervention: Follicle stimulating hormone (FSH)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Human menopausal gonadotropin (HMG)
Number of subjects: 232
Study: 2374772

Group type: EXPERIMENTAL
Intervention: Bright white light exposure for 7 days from 7.20 to 9.20 a.m.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dim light exposure
Number of subjects: 30
Study: 369263

Group type: EXPERIMENTAL
Intervention: Cimetidine: 1 gr./day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 36
Study: 30604111

Group type: EXPERIMENTAL
Intervention: e-book
Number of subjects: 30

Group type: COMPARATOR
Intervention: printed book
Number of subjects: 30
Study: 28252600

Group type: EXPERIMENTAL
Intervention: Neuromidin (ipidacrine)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 64
Study: 25686801

Group type: EXPERIMENTAL
Intervention: Psychoeducational family intervention
Number of subjects: 326

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 326
Study: 23585286

Group type: EXPERIMENTAL
Intervention: Sulpiride 100 mg dose
Number of subjects: 16
Study: 21757655

Group type: EXPERIMENTAL
Intervention: Baseline concentrations of circulating interleukin-10 (IL-10)
Number of subjects: 2437
Study: 19467958

Group type: EXPERIMENTAL
Intervention: ICEC‐R (randomised clinical trials comprehension inventory)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: STAI‐Y (trait-state anxiety scale)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: SAT (satisfaction about care scale)
Number of subjects: 474
Study: 16737398

Group type: EXPERIMENTAL
Intervention: Safety information
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Safety information plus safety cue
Number of subjects: 31

Group type: COMPARATOR
Intervention: No safety information
Number of subjects: 31
Study: 15574110

Group type: EXPERIMENTAL
Intervention: Upper Limb Group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mobility Group
Number of subjects: 30
Study: 11205487

Group type: EXPERIMENTAL
Intervention: Intervention group status (not specified in detail)
Number of subjects: 4477

Group type: EXPERIMENTAL
Intervention: Baseline perceived risk
Number of subjects: 4477

Group type: EXPERIMENTAL
Intervention: Current smoking status (for men without polyps)
Number of subjects: 4477

Group type: EXPERIMENTAL
Intervention: Year 2 perceived risk
Number of subjects: 4477

Group type: EXPERIMENTAL
Intervention: Belief in salience and coherence of screening (for men with polyps)
Number of subjects: 4477

Group type: EXPERIMENTAL
Intervention: Intention to be screened (for men with polyps)
Number of subjects: 4477

Group type: EXPERIMENTAL
Intervention: Access to screening at the worksite (for men with polyps)
Number of subjects: 4477

Group type: EXPERIMENTAL
Intervention: Specificity and sensitivity of models
Number of subjects: 4477
Study: 9421324

Group type: EXPERIMENTAL
Intervention: Penicillin for 10 days prior to surgery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cefprozil for 10 days prior to surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 60
Study: 8305993

Group type: EXPERIMENTAL
Intervention: Double-masked design
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Inclusion of all randomized patients
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Methodologic quality
Number of subjects: 102
Study: 3500684

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 62

Group type: COMPARATOR
Intervention: Antacids
Number of subjects: 62
Study: 29943744

Group type: EXPERIMENTAL
Intervention: Oral Vitamin D supplementation
Number of subjects: 948

Group type: EXPERIMENTAL
Intervention: Parenteral Vitamin D supplementation
Number of subjects: 948
Study: 28541588

Group type: EXPERIMENTAL
Intervention: Low-intensity walking protocol
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 78
Study: 25308883

Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage (MLD) sessions (10 sessions over 4 weeks)
Number of subjects: 41
Study: 23515684

Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study: 21617262

Group type: EXPERIMENTAL
Intervention: Chamomile solution (twice-a-day application)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Hydrocortisone 1% ointment (once-a-day application)
Number of subjects: 72
Study: 19725827

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 0
Study: 16894619

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER (75 mg/day or 150 mg/day)
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Paroxetine (40 mg/day)
Number of subjects: 664

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Active treatment (Venlafaxine ER or Paroxetine)
Number of subjects: 664
Study: 15215096

Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg per day
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 11800414

Group type: EXPERIMENTAL
Intervention: Captopril plus canreonate (25 mg/day)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Captopril alone (placebo)
Number of subjects: 187
Study: 9726220

Group type: EXPERIMENTAL
Intervention: Hemodiabsorption device (BioLogic‐DT System)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard intensive care procedures
Number of subjects: 11
Study: 7976145

Group type: EXPERIMENTAL
Intervention: Epidural analgesia initiated 30 min before surgical incision
Number of subjects: 32

Group type: COMPARATOR
Intervention: Epidural analgesia initiated at closure of the surgical wound
Number of subjects: 32
Study: 2658637

Group type: EXPERIMENTAL
Intervention: Ivermectin treatment (100, 150, or 200 micrograms/kg at 1 or 2 year intervals)
Number of subjects: 39
Study: 1092973

Group type: EXPERIMENTAL
Intervention: Diethylpropion hydrochloride (Tenuate Dospan)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Diethylpropion hydrochloride (Tenuate Dospan) after crossover to placebo
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo after crossover to diethylpropion hydrochloride
Number of subjects: 102
Study: 29641242

Group type: EXPERIMENTAL
Intervention: Acupuncture intervention (weekly or biweekly individualized treatments)
Number of subjects: 104
Study: 28967801

Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 14
Study: 26141682

Group type: EXPERIMENTAL
Intervention: Internet-supported cognitive behavioral therapy
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Bright light
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Body warming
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 23222967

Group type: EXPERIMENTAL
Intervention: Paula method (12 private lessons)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Pelvic floor muscle training (PFMT) (6 group lessons)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Paula method
Number of subjects: 143

Group type: COMPARATOR
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 143
Study: 21239142

Group type: EXPERIMENTAL
Intervention: Peer Review Intervention for Monitoring and Evaluating sites (PRIME)
Number of subjects: 8
Study: 18456558

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 720

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 720
Study: 16947627

Group type: EXPERIMENTAL
Intervention: Rituximab plus methotrexate (MTX)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 520